In 2018, burosumab (Crysvita®; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc., Novato, CA, USA), a human neutralizing antibody for FGF23 was approved for the treatment of XLH in adults and children older than 1 year and in 2020 for the treatment of tumor induced osteomalacia [139,140]. Here, FGF23 is linked to osteomalacia.